bumetanide has been researched along with Child Mental Disorders in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs)." | 9.51 | Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol. ( Bruining, H; Cristian, G; Geertjens, L; Haspels, E; Ramautar, J; van der Wilt, GJ; Verhage, M, 2022) |
| "Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC." | 6.94 | Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. ( Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020) |
| "Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs)." | 5.51 | Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol. ( Bruining, H; Cristian, G; Geertjens, L; Haspels, E; Ramautar, J; van der Wilt, GJ; Verhage, M, 2022) |
| "Before we elaborate on the postulated discrepancies between our trial and previous bumetanide in autism spectrum disorder (ASD) trials, we would like to acknowledge the crucial pioneering work on the γ-aminobutyric acid (GABA) developmental sequence by Dr." | 4.02 | Dr. Sprengers et al. Reply. ( Bruining, H; Sprengers, JJ; van Andel, DM, 2021) |
| "Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC." | 2.94 | Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. ( Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geertjens, L | 1 |
| Cristian, G | 1 |
| Haspels, E | 1 |
| Ramautar, J | 1 |
| van der Wilt, GJ | 1 |
| Verhage, M | 1 |
| Bruining, H | 3 |
| van Andel, DM | 2 |
| Sprengers, JJ | 2 |
| Oranje, B | 1 |
| Scheepers, FE | 1 |
| Jansen, FE | 1 |
2 trials available for bumetanide and Child Mental Disorders
| Article | Year |
|---|---|
Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol.
Topics: Bumetanide; Child; Cohort Studies; Humans; Neurodevelopmental Disorders; Research Design; Treatment | 2022 |
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.
Topics: Adolescent; Autism Spectrum Disorder; Bumetanide; Child; Disease Susceptibility; Duration of Therapy | 2020 |
1 other study available for bumetanide and Child Mental Disorders
| Article | Year |
|---|---|
Dr. Sprengers et al. Reply.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; gamma-Aminobutyric Acid; Humans; N | 2021 |